April 2026 Research Update

This month added two human studies suggesting that TTR-lowering treatments can keep nerve-related measures and daily-life function from getting worse over time, with similar patterns across different patient groups. One report in routine care followed people starting vutrisiran and found that neuropathy and quality of life scores did not show clear decline over 6 months. Another analysis of eplontersen in a clinical trial setting found similar treatment effects in men and women, including those who also had heart involvement. [1] [2]

In a real-world study of 25 people with ATTRv who started vutrisiran, quality of life and neuropathy scores stayed broadly similar between baseline and 6 months, and some measures moved in an improved direction even when the change was not statistically clear. Blood markers were described as largely maintained or improved, and TTR levels were maintained or reduced to undetectable levels in all patients. No treatment-related adverse events were reported in this short follow-up. [1]

In an exploratory sex-based analysis of eplontersen (another TTR-lowering medicine) from the NEURO-TTRansform trial, reductions in blood TTR were large and neuropathy impairment and nerve-related quality of life looked better than deterioration seen in a historical placebo comparison. The reported treatment effects were similar in male and female participants, and the same pattern was described in the subgroup who had cardiomyopathy. This narrows one practical uncertainty for patients: whether results differ by sex in this dataset. [2]

For patients and caregivers, these studies mainly add reassurance about consistency: in these reports, vutrisiran outcomes in routine care looked stable over 6 months, and eplontersen effects looked similar for men and women in an exploratory analysis. This does not prove what will happen for any individual, and both reports have limits (short follow-up for vutrisiran and subgroup/historical comparisons for the eplontersen analysis). What became clearer this month is that maintaining function and quality of life is being measured directly, and that some treatment effects may be broadly similar across sex and across trial versus routine-care settings, at least in the groups studied. [1] [2]

This month, multiple studies focused on finding ATTR involvement earlier and measuring it more clearly, using heart imaging, ECG-based computer models, blood markers of nerve injury, and a multi-organ scoring tool. Across these studies, the pattern is early signals: several approaches distinguished affected from unaffected groups, and some suggested they might detect changes before standard tests or before severe symptoms. At the same time, the studies also show that performance can vary by setting and that careful interpretation is still needed. [3] [4] [5] [6] [7]

For detecting heart involvement, a small study using 124I-evuzamitide PET/CT reported visible heart uptake in all amyloidosis participants who had cardiomyopathy, with no uptake in controls. In participants without known cardiomyopathy, most still showed uptake even when standard heart imaging tests were negative, suggesting this scan may pick up early or subtle cardiac involvement in some rare amyloidosis cases. The study was small, so this should be seen as an early signal rather than a settled diagnostic approach. [3]

Two studies examined computer-based detection from existing health data, aiming to flag people who might have ATTR-CM earlier. An ECG-based cloud model (Willem AI) separated ATTR-CM from controls with an AUC of 0.88 and had similar performance for hereditary and wild-type ATTR-CM, including some ability to detect early presentations. A separate study found that a billing-code-based model built in the US could identify ATTR-CM in a German dataset but with lower sensitivity and specificity and poor ability to separate hereditary from wild-type, showing that results depend strongly on which data are available and how they are coded. [4] [7]

For tracking nerve involvement, a Brazilian study reported that plasma neurofilament light chain (pNfL, a blood marker of nerve cell injury) was higher in symptomatic patients not on tafamidis than in tafamidis-treated symptomatic patients, asymptomatic carriers, and healthy controls. Higher pNfL also correlated with worse neuropathy impairment scores, and the authors reported that pNfL could help separate disease stages in their analyses. This supports pNfL as a possible tool for measuring nerve damage severity, but it was measured at one time point rather than followed over time. [5]

A prospective validation study introduced the modified-comprehensive Kumamoto Score (mKS), designed to rate multiple organ areas in ATTRv rather than focusing on only nerves or only the heart. The overall score tracked strongly with existing neuropathy and overall disease measures and with quality of life, and the separate subscales lined up with organ-specific markers (for example, the heart subscale with cardiac blood tests and imaging measures). Weak correlations between the subscales suggested the tool may help capture that different organs can be affected differently in the same person. [6]

A large Japanese registry report described what diagnostic workups looked like for 1,506 people with ATTR-CM, showing that noninvasive imaging and blood testing were used extensively alongside biopsy. Most registered cases were wild-type ATTR-CM and most patients were male, and many had multiple "red-flag" features recorded. While this study does not test a new tool, it adds a clearer picture of how ATTR-CM is being identified in routine practice within this registry. [8]

For patients, this set of studies mainly matters as progress toward earlier and clearer detection, plus better ways to follow how different organs are doing over time. Some approaches (a PET scan tracer, an ECG-based model, and a blood marker of nerve injury) showed they could separate groups with and without signs of disease, and one PET study reported uptake even when standard imaging was negative, which could matter in the future if confirmed in larger groups. What remains uncertain is how these tools perform across many hospitals and patient subtypes, and whether they reliably change outcomes when used in real care; one data-model study showed results dropped when moved to a different country and coding system. For now, these findings mostly add understanding and point to research directions rather than defining a new standard approach. [3] [4] [5] [6] [8] [7]

This month brought larger real-world datasets that help clarify how ATTRv shows up across families and across daily-life measures, including where uncertainty remains. One family-screening study showed that some symptom-free gene carriers do develop clinical ATTRv over time, sometimes earlier than expected, and patterns differed by genetic variant. Other studies showed that physical quality of life is often strongly affected while mental health scores may stay near population averages, and that nerve symptoms in a common variant (p.V142I) are often present but not always clearly due to amyloidosis. [9] [10] [11]

In an Italian multicenter cohort of 967 people from 431 families, 461 were asymptomatic gene carriers and 77 (16.7%) later developed clinical ATTRv. The study also reported that 11 of 62 converters developed disease more than 10 years earlier than predicted, which highlights that timing can be hard to forecast for an individual. The authors reported variant-specific differences in who converted, and they also reported better survival in diagnosed symptomatic carriers compared with index cases, with mixed-phenotype presentations doing worse than cardiac-only presentations. [9]

A long-running US center dataset of 836 people with ATTR amyloidosis found physical quality of life scores were markedly lower than population norms across ATTR subtypes, while mental health scores were close to average. The lowest physical scores were reported in V122I-ATTRv, a group that was predominantly Black in this dataset, and the most affected areas were limits in physical roles and reduced vitality (fatigue). This helps put numbers on an experience many patients describe: the body is affected more than mood or emotional well-being on average, even though individuals vary. [10]

A Penn cohort focused on the p.V142I TTR variant reported that polyneuropathy was common, but attribution to amyloidosis was much less common. Polyneuropathy was present in 41% of people with p.V142I, yet only 13% were judged possibly or probably due to amyloidosis, and even among those with cardiac amyloidosis that figure was 35%. This highlights a practical challenge for patients with this variant: numbness or tingling may have more than one possible cause, and careful evaluation affects how confidently symptoms are linked to ATTRv. [11]

For families affected by ATTRv, these studies add clearer expectations about variability: some gene carriers do convert to clinical disease over time, and the age of onset can be earlier than predicted for a minority of people, depending in part on the variant. They also add a clearer picture of lived impact, with physical function and energy often affected on surveys, while average mental health scores may be less disrupted. What remains uncertain is how to predict the course for any one person, and how best to separate ATTR-related nerve problems from other common causes, especially in p.V142I where co-existing conditions may explain symptoms for many patients. [9] [10] [11]

This month included individual-patient reports that mainly add detail about how ATTRv can look in specific tissues, and lab-based work that may help explain why symptoms vary between organs. One case report showed that eye (vitreous) amyloid can be confirmed by biopsy and lead to an ATTRv diagnosis. Another report used high-resolution imaging of amyloid taken from heart and liver tissue in one person and found different fibril shapes, which is a possible structural clue to why ATTR can behave differently across patients and organs. [12] [13]

In an 82-year-old man with vitreous amyloidosis, pathology on a vitreous biopsy confirmed amyloid material in the eye and supported the diagnosis of hereditary ATTRv amyloidosis. The report also discussed possible non-invasive imaging approaches for future diagnostics, but did not provide performance results for those approaches. As a single-patient experience, it mainly illustrates one pathway to diagnosis rather than defining what will happen for others. [12]

In laboratory analysis of amyloid taken from the heart and liver of a single person with an ATTRv V122Delta mutation, cryo-electron microscopy found that the amyloid fibrils were not all the same shape, with both single- and double-filament forms. The authors suggested that this kind of structural variety could be part of the biological reason for different disease patterns (for example, differences between organs or between patients). This is early mechanistic work and does not directly predict symptoms or treatment response. [13]

For patients, these reports mostly add to understanding rather than changing anything now. The eye case shows that ATTRv can involve the vitreous and that biopsy can confirm amyloid in that setting, which may matter when symptoms are unusual or diagnosis is uncertain. The fibril-structure study is mainly research that could help explain why ATTRv looks different from person to person or organ to organ, but it is based on tissue from only 1 patient and is not a test used in routine care. [12] [13]